153 related articles for article (PubMed ID: 24376589)
1. Patterns of anti-osteoporosis medication use among women at high risk of fracture: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW).
Gehlbach S; Hooven FH; Wyman A; Diez-Perez A; Adachi JD; Luo X; Bushmakin AG; Anderson FA;
PLoS One; 2013; 8(12):e82840. PubMed ID: 24376589
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for treatment failure with antiosteoporosis medication: the global longitudinal study of osteoporosis in women (GLOW).
Díez-Pérez A; Adachi JD; Adami S; Anderson FA; Boonen S; Chapurlat R; Compston JE; Cooper C; Gehlbach SH; Greenspan SL; Hooven FH; LaCroix AZ; Nieves JW; Netelenbos JC; Pfeilschifter J; Rossini M; Roux C; Saag KG; Silverman S; Siris ES; Wyman A; Rushton-Smith SK; Watts NB;
J Bone Miner Res; 2014 Jan; 29(1):260-7. PubMed ID: 23794198
[TBL] [Abstract][Full Text] [Related]
3. Characteristics associated with anti-osteoporosis medication use: data from the Global Longitudinal Study of Osteoporosis in Women (GLOW) USA cohort.
Guggina P; Flahive J; Hooven FH; Watts NB; Siris ES; Silverman S; Roux C; Pfeilschifter J; Greenspan SL; Díez-Pérez A; Cooper C; Compston JE; Chapurlat R; Boonen S; Adachi JD; Anderson FA; Gehlbach S;
Bone; 2012 Dec; 51(6):975-80. PubMed ID: 22964142
[TBL] [Abstract][Full Text] [Related]
4. Self-perception of fracture risk: what can it tell us?
Litwic AE; Compston JE; Wyman A; Siris ES; Gehlbach SH; Adachi JD; Chapurlat R; Díez-Pérez A; LaCroix AZ; Nieves JW; Netelenbos JC; Pfeilschifter J; Rossini M; Roux C; Saag KG; Silverman S; Watts NB; Greenspan SL; March L; Gregson CL; Cooper C; Dennison EM;
Osteoporos Int; 2017 Dec; 28(12):3495-3500. PubMed ID: 28861636
[TBL] [Abstract][Full Text] [Related]
5. Anti-osteoporosis medication treatment pattern after osteoporotic fracture during 2010-2016 in Fujian, China.
Wang X; Li C; He Y; Wang T; Zhang H; Ma Z; Ma H; Zhao H
Arch Osteoporos; 2020 Aug; 15(1):134. PubMed ID: 32820451
[TBL] [Abstract][Full Text] [Related]
6. Beyond bone mineral density, FRAX-based tailor-made intervention thresholds for therapeutic decision in subjects on glucocorticoid: A nationwide osteoporosis survey.
Yu SF; Chen JF; Chen YC; Lai HM; Ko CH; Chiu WC; Su FM; Hsu CY; Su BY; Wu CH; Cheng TT
Medicine (Baltimore); 2017 Feb; 96(5):e5959. PubMed ID: 28151883
[TBL] [Abstract][Full Text] [Related]
7. Cessation rate of anti-osteoporosis treatments and risk factors in Spanish primary care settings: a population-based cohort analysis.
Martín-Merino E; Huerta-Álvarez C; Prieto-Alhambra D; Montero-Corominas D
Arch Osteoporos; 2017 Dec; 12(1):39. PubMed ID: 28401495
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with treatment of women with osteoporosis or osteopenia from a national survey.
Meadows ES; Mitchell BD; Bolge SC; Johnston JA; Col NF
BMC Womens Health; 2012 Jan; 12():1. PubMed ID: 22225919
[TBL] [Abstract][Full Text] [Related]
9. Fracture rate associated with quality metric-based anti-osteoporosis treatment in glucocorticoid-induced osteoporosis.
Overman RA; Gourlay ML; Deal CL; Farley JF; Brookhart MA; Layton JB
Osteoporos Int; 2015 May; 26(5):1515-24. PubMed ID: 25600474
[TBL] [Abstract][Full Text] [Related]
10. Osteoporosis management and the utilization of FRAX®: a survey amongst health care professionals of the Asia-Pacific.
Korthoewer D; Chandran M;
Arch Osteoporos; 2012; 7():193-200. PubMed ID: 23225297
[TBL] [Abstract][Full Text] [Related]
11. Declining rates of osteoporosis management following fragility fractures in the U.S., 2000 through 2009.
Balasubramanian A; Tosi LL; Lane JM; Dirschl DR; Ho PR; O'Malley CD
J Bone Joint Surg Am; 2014 Apr; 96(7):e52. PubMed ID: 24695929
[TBL] [Abstract][Full Text] [Related]
12. The diagnostic threshold for osteoporosis impedes fracture prevention in women at high risk for fracture: A registry-based cohort study.
Leslie WD; Seeman E; Morin SN; Lix LM; Majumdar SR
Bone; 2018 Sep; 114():298-303. PubMed ID: 30008396
[TBL] [Abstract][Full Text] [Related]
13. Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW).
Díez-Pérez A; Hooven FH; Adachi JD; Adami S; Anderson FA; Boonen S; Chapurlat R; Compston JE; Cooper C; Delmas P; Greenspan SL; Lacroix AZ; Lindsay R; Netelenbos JC; Pfeilschifter J; Roux C; Saag KG; Sambrook P; Silverman S; Siris ES; Watts NB; Nika G; Gehlbach SH
Bone; 2011 Sep; 49(3):493-8. PubMed ID: 21605715
[TBL] [Abstract][Full Text] [Related]
14. Use of anti-osteoporosis medication dispensing by patients with hip fracture: could we do better?
Kristensen PK; Ehrenstein V; Shetty N; Pedersen AB
Osteoporos Int; 2019 Sep; 30(9):1817-1825. PubMed ID: 31263921
[TBL] [Abstract][Full Text] [Related]
15. Disparities in bone density measurement history and osteoporosis medication utilisation in Swiss women: results from the Swiss Health Survey 2007.
Born R; Zwahlen M
BMC Musculoskelet Disord; 2013 Jan; 14():10. PubMed ID: 23289751
[TBL] [Abstract][Full Text] [Related]
16. Predictors of treatment with osteoporosis medications after recent fragility fractures in a multinational cohort of postmenopausal women.
Greenspan SL; Wyman A; Hooven FH; Adami S; Gehlbach S; Anderson FA; Boone S; Lacroix AZ; Lindsay R; Netelenbos JC; Pfeilschifter J; Silverman S; Siris ES; Watts NB
J Am Geriatr Soc; 2012 Mar; 60(3):455-61. PubMed ID: 22316070
[TBL] [Abstract][Full Text] [Related]
17. Treatment Persistence and Medication Switch Associated With Subsequent Fractures After Osteoporotic Fractures.
Lin SY; Chen WJ; Ku CK; Chen YM; Chen CH; Chien LN
J Clin Endocrinol Metab; 2023 Dec; 109(1):e200-e208. PubMed ID: 37526298
[TBL] [Abstract][Full Text] [Related]
18. Physicians' perspectives on the treatment of osteoporosis patients with bisphosphonates.
Gu T; Eisenberg Lawrence DF; Stephenson JJ; Yu J
Clin Interv Aging; 2016; 11():1-8. PubMed ID: 26929609
[TBL] [Abstract][Full Text] [Related]
19. Patterns of pharmacotherapy and counseling for osteoporosis management in visits to US ambulatory care physicians by women.
Lee E; Zuckerman IH; Weiss SR
Arch Intern Med; 2002 Nov; 162(20):2362-6. PubMed ID: 12418951
[TBL] [Abstract][Full Text] [Related]
20. Trends in postmenopausal osteoporosis treatment in France during the period 2007-2016: A nationwide claims database analysis.
Cortet B; Schott AM; Désaméricq G; Chauny JV; Samama P; Emery C; Fagnani F
Bone; 2022 Jan; 154():116255. PubMed ID: 34763115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
